{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:04:59Z","timestamp":1782925499819,"version":"3.54.5"},"reference-count":41,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Technology &amp; Therapeutics"],"published-print":{"date-parts":[[2015,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Efficacy of basal insulin (BI) has been well studied by randomized controlled trials, but the impact of BI on glycemic control in the real world has not been well documented. The Observational Registry for BI Treatment (ORBIT) study is designed to evaluate the real-life outcomes of BI in China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      Participants with type 2 diabetes (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =19,894), from December 2011 to June 2013, inadequately controlled on oral hypoglycemic agents (OHAs) were initiated on BI treatment from 209 hospitals in all the eight regions in Mainland China. Data for each patient on use of OHAs and insulin (type and dose), glycemic control, hypoglycemic episodes, body weight, quality of life, and costs were collected at baseline and 3 and 6 months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>For the 18,995 participants who were eligible for baseline analysis, mean\u00b1SD age was 55.4\u00b110.4 years, with 52.5% males. The mean duration of diabetes was 6.4\u00b15.3 years and was positively associated with the economic level of eight regions. Before initiation of BI, patients had a mean hemoglobin A1c level of 9.6\u00b12.0% with a fasting plasma glucose level of 11.7\u00b14.0\u2009mmol\/L. Of the patients, 35.5% had some diabetes complications. Metformin, sulfonylureas, and \u03b1-glycosidase inhibitors were the most commonly used OHAs. The proportions of patients using one, two, or more than two OHAs before BI initiation were 48.4%, 42.7%, and 8.9%, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>To the best of our knowledge, the ORBIT study is the largest registry study to evaluate glycemic outcomes and safety of BI in real-world China. Baseline data indicate delays in initiation of BI in the majority of patients with type 2 diabetes in China.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/dia.2015.0054","type":"journal-article","created":{"date-parts":[[2015,7,14]],"date-time":"2015-07-14T14:34:27Z","timestamp":1436884467000},"page":"735-744","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":36,"title":["Observational Registry of Basal Insulin Treatment (ORBIT) in Patients with Type 2 Diabetes Uncontrolled by Oral Hypoglycemic Agents in China\u2014Study Design and Baseline Characteristics"],"prefix":"10.1177","volume":"17","author":[{"given":"Linong","family":"Ji","sequence":"first","affiliation":[{"name":"Peking University People's Hospital","place":["China"]},{"name":"The George Institute for Global Health at Peking University Health Science Center","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puhong","family":"Zhang","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health at Peking University Health Science Center","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Weng","sequence":"additional","affiliation":[{"name":"The Third Affiliated Hospital of Sun Yat-sen University","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juming","family":"Lu","sequence":"additional","affiliation":[{"name":"Chinese PLA General Hospital","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Guo","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiping","family":"Jia","sequence":"additional","affiliation":[{"name":"Shanghai 6th Hospital","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenying","family":"Yang","sequence":"additional","affiliation":[{"name":"China-Japan Friendship Hospital","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dajin","family":"Zou","sequence":"additional","affiliation":[{"name":"The Second Military Medical University","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiguang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Xiangya Second Hospital","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyu","family":"Pan","sequence":"additional","affiliation":[{"name":"Beijing 301 Military General Hospital","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Gao","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Li","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health at Peking University Health Science Center","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongshan","family":"Zhu","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health at Peking University Health Science Center","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health at Peking University Health Science Center","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangfeng","family":"Wu","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health at Peking University Health Science Center","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish K.","family":"Garg","sequence":"additional","affiliation":[{"name":"University of Colorado Denver"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2015,10,1]]},"reference":[{"key":"e_1_3_3_2_2","first-page":"678","article-title":"A mass survey of diabetes mellitus in a population of 300,000 in 14 provinces and municipalities in China [in Chinese] (author's transl)","volume":"20","author":"National Diabetes Research Group","year":"1981","unstructured":"National Diabetes Research Group: A mass survey of diabetes mellitus in a population of 300,000 in 14 provinces and municipalities in China [in Chinese] (author's transl). Zhonghua Nei Ke Za Zhi, 1981; 20:678\u2013683.","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908292"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-003-1167-8"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.20.11.1664"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.168118"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1306652"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.12088"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-13-602"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/753150"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2008.02503.x"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066224"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.5.995"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-004-0019-3"},{"key":"e_1_3_3_15_2","first-page":"393","article-title":"Starting insulin in type 2 diabetes: continue oral hypoglycemic agents? A randomized trial in primary care","volume":"53","author":"Goudswaard AN","year":"2004","unstructured":"Goudswaard AN, , Stolk RP, , Zuithoff P, et al.: Starting insulin in type 2 diabetes: continue oral hypoglycemic agents? A randomized trial in primary care. J Fam Pract, 2004; 53:393\u2013399.","journal-title":"J Fam Pract"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291401"},{"key":"e_1_3_3_17_2","first-page":"489","article-title":"Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta-cell function","volume":"70","author":"Mayfield JA","year":"2004","unstructured":"Mayfield JA, , White RD: Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta-cell function. Am Fam Physician, 2004; 70:489\u2013500.","journal-title":"Am Fam Physician"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.4158\/EP13176.CSUPPL"},{"key":"e_1_3_3_19_2","first-page":"54","article-title":"China guideline for type 2 diabetes (2010)","volume":"03","author":"Chinese Diabetes Society","year":"2011","unstructured":"Chinese Diabetes Society: China guideline for type 2 diabetes (2010). Chin J Front Med Sci (Electronic Version), 2011; 03:54\u2013109.","journal-title":"Chin J Front Med Sci (Electronic Version)"},{"key":"e_1_3_3_20_2","unstructured":"International Diabetes Federation 2012 Clinical Guidelines Task Force: Global Guideline for Type 2 Diabetes. 2012. www.idf.org\/sites\/default\/files\/IDF-Guideline-for-Type-2-Diabetes.pdf (accessed February11 2015)."},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-9025"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-S014"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2006.00674.x"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.78a.10051"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2013.862538"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2013.02.035"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1753-0407.2011.00137.x"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.12091"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2010.0063"},{"key":"e_1_3_3_30_2","unstructured":"National Glycohemoglobin Standardization Program: List of NGSP Certified Methods. www.ngsp.org\/docs\/methods.pdf (accessed January1 2015)."},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-4127"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.4158\/EP14061.OR"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2008.01742.x"},{"key":"e_1_3_3_34_2","first-page":"782","article-title":"Economic burden and economic risk of five major chronic diseases among Chinese urban residents [in Chinese]","volume":"46","author":"Liu M","year":"2014","unstructured":"Liu M, , Sun LH, , Liu G: Economic burden and economic risk of five major chronic diseases among Chinese urban residents [in Chinese]. Beijing Da Xue Xue Bao, 2014; 46:782\u2013789.","journal-title":"Beijing Da Xue Xue Bao"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2004.01395.x"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.11.2673"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.4158\/EP10323.OR"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1177\/0145721708317869"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0366-6999.20141432"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1177\/0145721705279050"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.12165"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802987"}],"container-title":["Diabetes Technology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/dia.2015.0054","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2015.0054","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2015.0054","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:15:50Z","timestamp":1777400150000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/dia.2015.0054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["10.1089\/dia.2015.0054"],"URL":"https:\/\/doi.org\/10.1089\/dia.2015.0054","relation":{},"ISSN":["1520-9156","1557-8593"],"issn-type":[{"value":"1520-9156","type":"print"},{"value":"1557-8593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10]]}}}